Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-FR Version v6-EN
Language French English
Date Updated 2022-06-27 2022-05-24
Drug Identification Number 02267659 02267659
Brand name ADENOSINE INJECTION ADENOSINE INJECTION
Common or Proper name ADENOSINE INJECTION ADENOSINE INJECTION
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients ADENOSINE ADENOSINE
Strength(s) 3MG 3MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 2ML 2ML
ATC code C01EB C01EB
ATC description OTHER CARDIAC PREPARATIONS OTHER CARDIAC PREPARATIONS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-06-01 2022-06-01
Estimated end date 2022-06-24 2022-06-24
Actual end date 2022-06-24
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to a shipping delay, we will be encountering a supply interruption on our Adenosine 3 mg/mL SD Vial 2 mL effective June 1, 2022 until June 24, 2022. During this time, allocations for our Adenosine Injection 3 mg/mL prefilled syringe 2 mL will be increased. Contract customers will be allocated 100% of historical 2 mL syringe demand plus 100% of 2 mL vial demand. Fresenius Kabi Canada regrets to advise that due to a shipping delay, we will be encountering a supply interruption on our Adenosine 3 mg/mL SD Vial 2 mL effective June 1, 2022 until June 24, 2022. During this time, allocations for our Adenosine Injection 3 mg/mL prefilled syringe 2 mL will be increased. Contract customers will be allocated 100% of historical 2 mL syringe demand plus 100% of 2 mL vial demand.
Health Canada comments